Cargando…

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

BACKGROUND: Despite advances in targeted agent development, effective treatment of acute myeloid leukemia (AML) remains a major clinical challenge. The B-cell lymphoma-2 (BCL-2) inhibitor exhibited promising clinical activity in AML, acute lymphoblastic leukemia (ALL) and diffuse large B-cell lympho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Wenwen, Huang, Shujuan, Ling, Qing, Mao, Shihui, Qian, Yu, Ye, Wenle, Li, Fenglin, Pan, Jiajia, Lin, Xiangjie, Huang, Jiansong, Huang, Xin, Zhai, Yifan, Sun, Jie, Jin, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258085/ https://www.ncbi.nlm.nih.gov/pubmed/35794605 http://dx.doi.org/10.1186/s12967-022-03497-2

Ejemplares similares

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD
por: Qian, Yu, et al.
Publicado: (2023)

Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199
por: Mao, Shihui, et al.
Publicado: (2021)

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020)

Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022)

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance
por: Li, Fenglin, et al.
Publicado: (2022)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

Global, regional, and national burdens of leukemia from 1990 to 2017: a systematic analysis of the global burden of disease 2017 study
por: Lin, Xiangjie, et al.
Publicado: (2021)

P1106: PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS)
por: Sun, M., et al.
Publicado: (2022)

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
por: Huang, Shujuan, et al.
Publicado: (2020)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway
por: Ling, Qing, et al.
Publicado: (2021)

Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia
por: Wang, Jinghan, et al.
Publicado: (2021)

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis
por: Li, Fenglin, et al.
Publicado: (2023)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
por: Yi, Hanjie, et al.
Publicado: (2020)

Dihydropyrimidinase‐like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia
por: Li, Fenglin, et al.
Publicado: (2023)

Wetting Mechanism and Experimental Study of Synergistic Wetting of Bituminous Coal with SDS and APG1214
por: Sun, Liying, et al.
Publicado: (2021)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy
por: Zhang, Yanyu, et al.
Publicado: (2020)

Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense
por: Zhang, Jingjing, et al.
Publicado: (2019)

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis
por: Zhang, Jing, et al.
Publicado: (2015)

Correction to “Wetting Mechanism and Experimental Study of Synergistic Wetting of Bituminous Coal with SDS and APG1214”
por: Sun, Liying, et al.
Publicado: (2022)

Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
por: Wang, Qian, et al.
Publicado: (2017)

The Waitangi Tribunal’s WAI 2575 Report: Implications for Decolonizing Health Systems
por: Came, Heather, et al.
Publicado: (2020)

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
por: Li, Xia, et al.
Publicado: (2018)

Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism
por: Wang, Fenglin, et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Correction to: Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
por: Luo, Fan, et al.
Publicado: (2021)

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis
por: Yao, Weilong, et al.
Publicado: (2022)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
por: Nguyen, Tri, et al.
Publicado: (2018)

Homoharringtonine regulates the alternative splicing of Bcl-x and caspase 9 through a protein phosphatase 1-dependent mechanism
por: Sun, Qi, et al.
Publicado: (2018)

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
por: Chen, Zide, et al.
Publicado: (2018)

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
por: Fang, Douglas D., et al.
Publicado: (2021)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
por: Bivol, Svetlana, et al.
Publicado: (2022)

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development
por: Yao, Yiyi, et al.
Publicado: (2021)

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma
por: Wolff, Nicholas C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c2fpvdcetfsrgcuviqov7sjnvu